{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:01:19Z","timestamp":1782774079788,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T00:00:00Z","timestamp":1248912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Aggressive non-melanoma skin cancer (deeply infiltrating, recurrent, and morphea form lesions) are therapeutically challenging because they require considerable tissue loss and may demand radical disfiguring surgery. Interferons (IFN) may provide a non-surgical approach to the management of these tumors. The aim of this work was to evaluate the effect of a formulation containing IFNs-\u03b1 and -\u03b3 in synergistic proportions on patients with recurrent, advanced basal cell (BCC) or squamous cell skin carcinomas (SCSC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with extensive, recurrent, resistant to other procedures BCC or SCSC received the IFN formulation peri- and intralesionally, three times per week for 3 weeks. They had been previously treated with surgery and\/or radiotherapy or chemotherapy. Thirteen weeks after the end of treatment, the original lesion sites were examined for histological evidence of remaining tumor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Sixteen elder (median 70 years-old) patients were included. They beared 12 BCC and 4 SCSC ranging from 1.5 to 12.5 cm in the longest dimension. At the end of treatment 47% CR (complete tumor elimination), 40% PR (&gt;30% tumor reduction), and 13% stable disease were obtained. None of the patients relapsed during the treatment period. The median duration of the response was 38 months. Only one patient with complete response had relapsed until today. Principal adverse reactions were influenza-like symptoms well known to occur with interferon therapy, which were well tolerated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The peri- and intralesional combination of IFNs-\u03b1 and -\u03b3 was safe and showed effect for the treatment of advanced, recurrent and resistant to previous treatments of BCC and SCSC in elder patients. This is the first report of such treatment in patients with advance non-melanoma skin cancer. The encouraging result justifies further confirmatory trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>Current Controlled Trials RPCEC00000052.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-9-262","type":"journal-article","created":{"date-parts":[[2009,7,30]],"date-time":"2009-07-30T18:15:18Z","timestamp":1248977718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study"],"prefix":"10.1186","volume":"9","author":[{"given":"Lorenzo","family":"Anasagasti-Angulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanelda","family":"Garcia-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Barcelona-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Lopez-Saura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraldo","family":"Bello-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,30]]},"reference":[{"key":"1596_CR1","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/bmj.327.7418.794","volume":"327","author":"CS Wong","year":"2003","unstructured":"Wong CS, Strange RC, Lear JT: Basal cell carcinoma. BMJ. 2003, 327: 794-798. 10.1136\/bmj.327.7418.794.","journal-title":"BMJ"},{"key":"1596_CR2","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0190-9622(94)70259-4","volume":"31","author":"Y Oram","year":"1994","unstructured":"Oram Y, Orengo Y, Alford E, Grean LK, Netscher DT: Basal cell carcinoma of the scalp resulting in spine metastasis in black patients. J Am Acad Dermatol. 1994, 31: 916-920. 10.1016\/S0190-9622(94)70259-4.","journal-title":"J Am Acad Dermatol"},{"key":"1596_CR3","first-page":"348","volume":"18","author":"LA Skelton","year":"2009","unstructured":"Skelton LA: The effective treatment of basal cell carcinoma. Br J Nurs. 2009, 18: 348-350.","journal-title":"Br J Nurs"},{"key":"1596_CR4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1046\/j.1365-2133.2002.04844.x","volume":"146","author":"ED Baron","year":"2002","unstructured":"Baron ED, Stevens SR: Sunscreens and immune protection. Br J Dermatol. 2002, 146: 933-937. 10.1046\/j.1365-2133.2002.04844.x.","journal-title":"Br J Dermatol"},{"key":"1596_CR5","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1046\/j.1524-4725.2003.29295.x","volume":"29","author":"AA Gaspari","year":"2003","unstructured":"Gaspari AA, Sauder DN: Immunotherapy of Basal Cell Carcinoma: Evolving Approaches. Dermatol Surg. 2003, 29: 1027-1034. 10.1046\/j.1524-4725.2003.29295.x.","journal-title":"Dermatol Surg"},{"key":"1596_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/carcin\/bgn228","volume":"30","author":"CY Chu","year":"2009","unstructured":"Chu CY, Cha ST, Lin WC, Lu PH, Tan CT, Chang CC, Lin BR, Jee SH, Kuo ML: Stromal cell-derived factor-1alpha (SDF-1alpha\/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1\/2-NF-kappaB\/interleukin-6 pathway. Carcinogenesis. 2009, 30: 205-213. 10.1093\/carcin\/bgn228.","journal-title":"Carcinogenesis"},{"key":"1596_CR7","unstructured":"Skin Cancer. 2007, Keyvan Nouri MD McGraw Hill"},{"key":"1596_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1101\/gad.1258705","volume":"19","author":"ME Hutchin","year":"2005","unstructured":"Hutchin ME, Kariapper MS, Grachtchouk M, Wang A, Wei L, Cummings D, Liu J, Michael LE, Glick A, Dlugosz AA: Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005, 19: 214-223. 10.1101\/gad.1258705.","journal-title":"Genes Dev"},{"key":"1596_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s004170000221","volume":"239","author":"JM Rohrbach","year":"2001","unstructured":"Rohrbach JM, Stiemer R, Mayer A, Riedinger C, Duijvestijn A, Zierhut M: Immunology and growth characteristics of ocular basal cell carcinoma. Graefe's Arch Clin Exp Ophthalmol. 2001, 239: 35-40. 10.1007\/s004170000221.","journal-title":"Graefe's Arch Clin Exp Ophthalmol"},{"key":"1596_CR10","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1172\/JCI119814","volume":"100","author":"Stanislaw A Buechner","year":"1997","unstructured":"Buechner Stanislaw, Wernli Marion, Harr Thomas, Hahn Sinuhe, Itin Peter, Erb Peter: Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1\/Fas)-CD95 ligand-induced suicide. J Clin Invest. 1997, 100: 2691-2696. 10.1172\/JCI119814.","journal-title":"J Clin Invest"},{"key":"1596_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1023\/B:CANC.0000031775.04618.30","volume":"23","author":"OW Walling","year":"2004","unstructured":"Walling OW, Fosko Scott, Geraminejad Pedram, Whitaker Duane, Arpey Christopher: Aggressive basal cell carcinoma: Presentation, pathogenesis, and management. Cancer and Metastasis Reviews. 2004, 23: 389-402. 10.1023\/B:CANC.0000031775.04618.30.","journal-title":"Cancer and Metastasis Reviews"},{"key":"1596_CR12","unstructured":"D Gross N, Monroe M: Skin Cancer: Squamous Cell Carcinoma. [http:\/\/emedicine.medscape.com]"},{"key":"1596_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1001\/archderm.143.7.889","volume":"143","author":"JE Bauman","year":"2007","unstructured":"Bauman JE, Eaton KD, Martins RG: Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007, 143: 889-892. 10.1001\/archderm.143.7.889.","journal-title":"Arch Dermatol"},{"key":"1596_CR14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/0190-9622(90)70276-N","volume":"23","author":"RC Cornell","year":"1990","unstructured":"Cornell RC, Greenway HT, Tucker SB, Edwards L, Ashworth S, Vance JC, Tanner DJ, Taylor EL, Smiles KA, Peets EA: Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990, 23: 694-700. 10.1016\/0190-9622(90)70276-N.","journal-title":"J Am Acad Dermatol"},{"key":"1596_CR15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1001\/archderm.1992.01680210064008","volume":"128","author":"L Edwards","year":"1992","unstructured":"Edwards L, Berman B, Rapini RP, Whiting DA, Tyring S, Greenway HT, Eyre SP, Tanner DJ, Taylor EL, Peets E, Smiles KA: Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy. Arch Dermatol. 1992, 128: 1486-1489. 10.1001\/archderm.128.11.1486.","journal-title":"Arch Dermatol"},{"key":"1596_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1524-4725.2004.30020.x","volume":"30","author":"K Kim","year":"2004","unstructured":"Kim K, Yavel R, Gross V, Brody N: Intralesional interferon a-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: Revisited. Dermatologic Surgery. 2004, 30: 116-120. 10.1111\/j.1524-4725.2004.30020.x.","journal-title":"Dermatologic Surgery"},{"key":"1596_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jaad.2006.02.035","volume":"54","author":"S Tucker","year":"2006","unstructured":"Tucker S, Polasek J, Perri A, Goldsmith E: Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. J Am Acad Dermatol. 2006, 54: 1033-1038. 10.1016\/j.jaad.2006.02.035.","journal-title":"J Am Acad Dermatol"},{"key":"1596_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0190-9622(92)70158-C","volume":"27","author":"B Stenquist","year":"1992","unstructured":"Stenquist B, Wennberg A, Gisslen H, Larko O: Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol. 1992, 27: 65-69. 10.1016\/0190-9622(92)70158-C.","journal-title":"J Am Acad Dermatol"},{"key":"1596_CR19","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2006.05.9873","volume":"25","author":"AM Brewster","year":"2007","unstructured":"Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM: Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007, 25: 1974-1978. 10.1200\/JCO.2006.05.9873.","journal-title":"J Clin Oncol"},{"key":"1596_CR20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/j.1460-2075.1990.tb08216.x","volume":"9","author":"DE Levy","year":"1990","unstructured":"Levy DE, Lew DJ, Decker T, Kessler DS, Darnell JE: Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 1990, 9: 1105-1111.","journal-title":"EMBO J"},{"key":"1596_CR21","first-page":"427","volume-title":"Interferons principles and medical applications","author":"JR Quesada","year":"1992","unstructured":"Quesada JR: Toxicity and side effects of interferons. Interferons principles and medical applications. Edited by: Baron S, Coppenhaver DH, Dianzani F. 1992, The University of Texas Medical Branch at Galveston, Texas, 427-432."},{"key":"1596_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00002018-199410020-00003","volume":"10","author":"T Vial","year":"1994","unstructured":"Vial T, Descotes J: Clinical toxicity of the interferons. Drug safety. 1994, 10: 115-150. 10.2165\/00002018-199410020-00003.","journal-title":"Drug safety"},{"key":"1596_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa053007","volume":"16","author":"H Gogas","year":"2006","unstructured":"Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM: Prognostic Signficance of Autoimmunity during treatment of Melanoma with Interferon. NEJM. 2006, 16: 709-718. 10.1056\/NEJMoa053007.","journal-title":"NEJM"},{"key":"1596_CR24","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a single formula based on renal function. J Clin Oncol. 1989, 7: 1748-1756.","journal-title":"J Clin Oncol"},{"key":"1596_CR25","volume-title":"Gu\u00eda de Recomendaciones","author":"Sociedad Argentina de Dermatolog\u00eda","year":"2005","unstructured":"Sociedad Argentina de Dermatolog\u00eda: Consenso sobre Carcinoma Basocelular Carcinoma Espinocelular. Gu\u00eda de Recomendaciones. 2005, 10.1038\/modpathol.3800512. [http:\/\/www.sad.org.ar\/revista\/pdf\/]"},{"key":"1596_CR26","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1038\/modpathol.3800512","volume":"19","author":"N Crowson","year":"2006","unstructured":"Crowson N: Basal Cell Carcinoma: biology, morphology and clinical implications. Modern Pathology. 2006, 19: S127-S147. 10.1023\/B:CANC.0000031775.04618.30.","journal-title":"Modern Pathology"},{"key":"1596_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1023\/B:CANC.0000031775.04618.30","volume":"23","author":"HW Walling","year":"2004","unstructured":"Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ: Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004, 23: 389-402. 10.1023\/B:CANC.0000031775.04618.30.","journal-title":"Cancer Metastasis Rev"},{"key":"1596_CR28","volume-title":"Ministerio de Salud P\u00fablica Direcci\u00f3n Nacional de Estad\u00edstica","author":"Anuario Estad\u00edstico de Salud","year":"2004","unstructured":"Anuario Estad\u00edstico de Salud: Ministerio de Salud P\u00fablica Direcci\u00f3n Nacional de Estad\u00edstica. 2004, [http:\/\/www.cigb.edu.cu\/]"},{"key":"1596_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/BF00159865","volume":"25","author":"M Neudorfer","year":"1993","unstructured":"Neudorfer M, Merimsky O, Lazar M, Geyer O: Cisplatin and doxorubicin for invasive basal cell carcinoma of the eyelids. Ann Ophthalmol. 1993, 25: 11-13. 10.1007\/BF00159865.","journal-title":"Ann Ophthalmol"},{"key":"1596_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/BF00159865","volume":"14","author":"WM Amoaku","year":"1990","unstructured":"Amoaku WM, Bagegni A, Logan WC, Archer DB: Orbital infiltration by eyelid skin carcinoma. Int Ophthalmol. 1990, 14: 285-294. 10.1016\/j.ophtha.2004.11.036.","journal-title":"Int Ophthalmol"},{"key":"1596_CR31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ophtha.2004.11.036","volume":"112","author":"I Leibovitch","year":"2005","unstructured":"Leibovitch I, McNab A, Sullivan T, Davis G, Selva D: Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005, 112: 717-723. 10.1016\/0190-9622(92)70158-C.","journal-title":"Ophthalmology"},{"key":"1596_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0190-9622(92)70158-C","volume":"27","author":"B Stenquist","year":"1992","unstructured":"Stenquist B, Wennberg A, Gisslen H, Larko O: Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery. J Am Acad Dermatol. 1992, 27: 65-69. 10.1016\/0190-9622(92)70158-C.","journal-title":"J Am Acad Dermatol"},{"key":"1596_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.2165\/00003495-199550010-00005","volume":"12","author":"L Kowalzick","year":"2002","unstructured":"Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, Fierlbeck G, Mohr P, Ochsendorf F, Wagner G, Gaus W, Brzoska J, Jablonska S: Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: Results of an open-label multicentre study. Eur J Dermatol. 2002, 12: 558-561. 10.2165\/00003495-199550010-00005.","journal-title":"Eur J Dermatol"},{"key":"1596_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2165\/00003495-199550010-00005","volume":"50","author":"R Marks","year":"1995","unstructured":"Marks R, Motley RJ: Skin cancer. Recognition and treatment. Drugs. 1995, 50: 48-61. 10.1007\/s00432-004-0656-6.","journal-title":"Drugs"},{"key":"1596_CR35","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00432-004-0656-6","volume":"131","author":"U Wollina","year":"2005","unstructured":"Wollina U, Hansel G, Koch A, K\u00f6stler E: Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol. 2005, 131: 300-304. 10.1034\/j.1600-0420.2002.800623_3.x.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1596_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1034\/j.1600-0420.2002.800623_3.x","volume":"80","author":"S Fenton","year":"2002","unstructured":"Fenton S, Kennedy S, Moriarty P: The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids. Acta Ophthalmologica Scandinavica. 2002, 80: 674-675. 10.1080\/028418699431203.","journal-title":"Acta Ophthalmologica Scandinavica"},{"key":"1596_CR37","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/028418699431203","volume":"38","author":"AD Roth","year":"1999","unstructured":"Roth AD, Morant R, Alberto P: High Dose Etretinate and Interferon-alpha: A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas. Acta Oncol. 1999, 38: 613-618. 10.1080\/028418699431203.","journal-title":"Acta Oncol"},{"key":"1596_CR38","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1200\/JCO.1990.8.10.1637","volume":"1","author":"M Ernstoff","year":"1990","unstructured":"Ernstoff M, Nair S, Bahnson R, Miketic L, Banner B, Gooding W, Day R, Whiteside T, Hakala T, Kirkwood JM: A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. JCO. 1990, 1: 1637-1649.","journal-title":"JCO"},{"key":"1596_CR39","first-page":"191","volume":"21","author":"F Novelli","year":"1997","unstructured":"Novelli F, Allione A, Bernabei P, Rigamonti L, Forni G: Antiblastic chemotherapy drugs up-modulate interferon-gamma receptor expression on human malignant T cells. Cancer Detect Prev. 1997, 21: 191-195.","journal-title":"Cancer Detect Prev"},{"key":"1596_CR40","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/BF01740941","volume":"25","author":"JI Johnsen","year":"2004","unstructured":"Johnsen JI, Pettersen I, Ponthan F, Sveinbjornsson B, Flaegstad T, Kogner P: Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol. 2004, 25: 1849-1857. 10.1007\/BF01740941.","journal-title":"Int J Oncol"},{"key":"1596_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF01740941","volume":"31","author":"PHM de Mulder","year":"1990","unstructured":"de Mulder PHM, Debruyne FMJ, Franssen MPH, Geboers ADH, Strijk S, Reintjes Ad GM, Doesburg WH, Damsma O: Phase I\/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma. Cancer Immunol Immunother. 1990, 31: 321-324. 10.1007\/BF01740941.","journal-title":"Cancer Immunol Immunother"},{"key":"1596_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/CJI.0b013e3181818769","volume":"22","author":"HX Tong","year":"2007","unstructured":"Tong HX, Lu CW, Zhang JH, Ma L, Zhang JH: Combination of gamma-interferon with trail and cisplatin or etoposide induces apoptosis in human neuroblastoma cell line SH-SY5Y. Chin Med Sci J. 2007, 22: 38-43. 10.1097\/CJI.0b013e3181818769.","journal-title":"Chin Med Sci J"},{"key":"1596_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/CJI.0b013e3181818769","volume":"31","author":"Y Zhu","year":"2008","unstructured":"Zhu Y, Tibensky I, Schmidt J, Ryschich E, M\u00e4rten A: Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother. 2008, 31: 599-606. 10.1097\/CJI.0b013e318157c682.","journal-title":"J Immunother"},{"key":"1596_CR44","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/CJI.0b013e318157c682","volume":"31","author":"Y Zhu","year":"2008","unstructured":"Zhu Y, Tibensky I, Schmidt J, Hackert T, Ryschich E, J\u00e4ger D, B\u00fcchler MW, M\u00e4rten A: Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother. 2008, 31: 28-33. 10.1097\/CJI.0b013e318157c682.","journal-title":"J Immunother"},{"key":"1596_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archderm.126.12.1660","volume":"8","author":"TH Guthrie Jr","year":"1990","unstructured":"Guthrie TH, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR: Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: Results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990, 8: 342-346. 10.1001\/archderm.126.12.1660.","journal-title":"J Clin Oncol"},{"key":"1596_CR46","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1001\/archderm.1990.01670360128037","volume":"126","author":"JD Khandekar","year":"1990","unstructured":"Khandekar JD: Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report on two patients (letter). Arch Dermatol. 1990, 126: 1660-10.1016\/0190-9622(91)70108-E.","journal-title":"Arch Dermatol"},{"key":"1596_CR47","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/0190-9622(91)70108-E","volume":"24","author":"JS Lo","year":"1991","unstructured":"Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ: Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991, 24: 715-719. 10.1016\/0190-9622(91)70108-E.","journal-title":"J Am Acad Dermatol"},{"key":"1596_CR48","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1524-4725.1989.tb03166.x","volume":"15","author":"DE Rowe","year":"1989","unstructured":"Rowe DE, Carroll RJ, Day CL: Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989, 15: 315-328. 10.1016\/S0733-8635(05)70020-6.","journal-title":"J Dermatol Surg Oncol"},{"key":"1596_CR49","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0733-8635(05)70020-6","volume":"16","author":"R Stadler","year":"1998","unstructured":"Stadler R: Interferons in dermatology. Present-day standard. Dermatol Clin. 1998, 16: 377-398. 10.1093\/jnci\/84.4.235.","journal-title":"Dermatol Clin"},{"key":"1596_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/jnci\/84.4.235","volume":"84","author":"SM Lippman","year":"1992","unstructured":"Lippman SM, Donovan DT, Frankenthaler RA, Weber RS, Earley CL, Hong WK, Goepfert H: 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992, 84: 235-241. 10.1200\/JCO.2006.05.9873.","journal-title":"J Natl Cancer Inst"},{"key":"1596_CR51","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2006.05.9873","volume":"25","author":"AM Brewster","year":"2007","unstructured":"Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM: Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007, 25: 1974-1978. 10.1200\/JCO.2006.05.9873.","journal-title":"J Clin Oncol"},{"key":"1596_CR52","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0002-9440(10)64424-0","volume":"161","author":"JL Hui","year":"2002","unstructured":"Hui JL, Kluger MS, Madge LA, Lian Z, Bothwell ALM, Pober JS: Interferon-gamma augments CD95(APO-1\/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis. Am J Path. 2002, 161: 1485-1495.","journal-title":"Am J Path"},{"key":"1596_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1126\/science.288.5475.2357","volume":"65","author":"D Sypniewski","year":"2008","unstructured":"Sypniewski D, Bednarek I, Ga ka S, Loch T, Machnik G: Influence of interferon-alpha and ribavirin on the transcription of interferon-gamma and IFN-gamma receptor genes in Jurkat cells. Acta Pol Pharm. 2008, 65: 345-351. 10.1126\/science.288.5475.2357.","journal-title":"Acta Pol Pharm"},{"key":"1596_CR54","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1126\/science.288.5475.2357","volume":"30","author":"A Takaoka","year":"2000","unstructured":"Takaoka A, Mitani Y, Suemori H, Sato M, Yokochi T, Shigeru , Tanaka N, Taniguchi T: Cross talk between interferon-gamma and -alpha\/beta signaling components in caveolar membrane domains. Science. 2000, 30: 2357-2360. 10.1126\/science.288.5475.2357.","journal-title":"Science"},{"key":"1596_CR55","first-page":"2726","volume":"5","author":"JW Slaton","year":"1999","unstructured":"Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999, 5: 2726-2734.","journal-title":"Clin Cancer Res"},{"key":"1596_CR56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4049\/jimmunol.164.1.217","volume":"164","author":"HM Fathallah-Shaykh","year":"2000","unstructured":"Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM, Forman J: Gene transfer of IFN-\u03b3 into established brain tumors represses growth by antiangiogenesis. J Immunol. 2000, 164: 217-222. 10.1158\/1078-0432.CCR-04-1470.","journal-title":"J Immunol"},{"key":"1596_CR57","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1158\/1078-0432.CCR-04-1470","volume":"11","author":"A Katayama","year":"2005","unstructured":"Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y: Expression of CXCR4 and Its Down-Regulation by IFN-\u03b3 in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2005, 11: 2937-2946. 10.1038\/nrc1782.","journal-title":"Clin Cancer Res"},{"key":"1596_CR58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser KE, Eichten A, Coussens LM: Paradoxical Roles of the Immune System During Cancer Development. Nat Rev Cancer. 2006, 6: 24-37. 10.1038\/nrc1782.","journal-title":"Nat Rev Cancer"},{"key":"1596_CR59","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1089\/10799900260100222","volume":"22","author":"JL Brown","year":"2002","unstructured":"Brown JL, Barsoum J, Qin XQ: CD4+ T Helper Cell-Independent Antitumor Response Mediated by Murine IFN-\u03b2 Gene Delivery in Immunocompetent Mice. Journal of Interferon & Cytokine Research. 2002, 22: 719-728. 10.1089\/10799900260100222.","journal-title":"Journal of Interferon & Cytokine Research"},{"key":"1596_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","volume":"13","author":"F Belardellia","year":"2002","unstructured":"Belardellia F, Ferrantinia M, Proiettia E, Kirkwoodb JM: Interferon-alpha in tumor immunity and immunotherapy. Cytokine and growth factor. 2002, 13: 119-134. 10.1016\/S1359-6101(01)00022-3.","journal-title":"Cytokine and growth factor"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-9-262\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-9-262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T10:34:48Z","timestamp":1630492488000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-9-262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,30]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-9-262","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,30]]},"assertion":[{"value":"3 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"262"}}